In the way we’re structured, in the people we hire, in our trials and technology—and in the way we research and innovate transformative solutions on the frontiers of oncology and autoimmune disease.
Shifting toward disease-centric therapies, we seek to treat patients holistically, allowing us to target diseases and their consequences on the human body on multiple levels.
MULTIPLE MYELOMA (MM)
The current cancer treatment landscape is carved from centuries of scientific knowledge, gained by those dedicated to advancing a greater understanding of the human body. Diagnoses once thought incurable have now shifted, with new thinking, new research, new therapies, and new discoveries made possible by those who walked the path of innovation before us.1
Now, it’s our turn. We’re pioneering advancements in oncology that enhance the immune system’s ability to detect and kill cancer. Born from our patented BEAT® (Bispecific Engagement by Antibodies based on the T-cell receptor) technology platform, our immuno-oncology assets currently in Phase 1 clinical trials facilitate binding of powerful immune cells called CD3 (or T cells) to HER2- and CD38-expressing tumors.2 This may allow for the treatment of cancers such as breast and multiple myeloma, including those non-responsive or resistant to standard care.
Together with our biologics discovery work, our strategy for the creation of small molecules that may address new targets and traditionally undruggable targets places us on a path to innovation that holds great promise for the future.*
We believe that we can find ways to treat cancer differently.
*Ichnos research on small molecules is conducted by Glenmark Pharmaceuticals Ltd. through a service agreement.
At Ichnos Sciences, we’re working to change the therapeutic approaches of autoimmune diseases.
With a deep understanding of the body’s aberrant autoimmune response that leads to the immune system attacking healthy cells and causing inflammation, our molecule, ISB 830, is designed to block the key immune system activation factor, OX-40.3 By blocking OX-40 on the surface of T cells, ISB 830 down-regulates overactive T cells to “normalize” their activity and slow the immune system’s auto-reactive responses, reducing symptoms of autoimmune disease.3
Currently in Phase 2b clinical trials for atopic dermatitis, ISB 830 offers an entirely new mechanism of action to treat autoimmune disease and has the potential to address a range of conditions.4 The treatment may change lives, and the way autoimmune diseases are treated—from now on.
Note: Assets that were previously identified as GBR and GRC are now identified as ISB (for biologics) and ISC (for small molecules), respectively.